| Chemical Properties | Back Directory | [Boiling point ]
556.7±50.0 °C(Predicted) | [density ]
1.32±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
11.67±0.43(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Description]
BAY1830839 is a novel potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor (IC50 of 3 nM). | [Uses]
IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research[1]. | [in vivo]
IRAK4-IN-20 (Compound BAY-1834845) (150 mg/kg; p.o.; once or twice) effectively prevents acute respiratory distress syndrome in mice[1]. | Animal Model: | Female Balb/c mice (aged 6–7 weeks), LPS-induced ARDS mouse model[1] | | Dosage: | 150 mg/kg | | Administration: | Oral administration, 30 min before LPS modeling or twice 4 h and 12 h after LPS modeling | | Result: | Remarkably decreased inflammatory cells infiltrating lung tissue and neutrophil count in BALF.
Effectively reduced the numbers of total T cells, monocyte, and macrophages.
Largely preserved the signatures of na?ve lymphocytes and stromal cells such as endothelial cells, chondrocytes, and smooth muscle cells.
Regulated inflammation and innate immunity genes more efficiently than Dexamethasone (HY-14648).
|
| [IC 50]
IRAK4: 3.55 nM (IC50) | [References]
[1] Li Q, et al. Oral IRAK4 Inhibitor BAY-1834845 Prevents Acute Respiratory Distress Syndrome. Biomedicine & Pharmacotherapy, 2022: 113459. |
|
|